Analysts have been eager to weigh in on the Healthcare sector with new ratings on Fresenius Medical Care AG & Co. KGaA (GB:0H9X – Research Report), Shop Apotheke Europe NV (GB:0RJT – Research Report) and Scholar Rock Holding (SRRK – Research Report).
Fresenius Medical Care AG & Co. KGaA (GB:0H9X)
In a report released yesterday, James Vane from Jefferies maintained a Sell rating on Fresenius Medical Care AG & Co. KGaA, with a price target of EUR21.00. The company’s shares closed yesterday at EUR46.80.
According to TipRanks.com, Vane is ranked #7745 out of 24810 analysts.
Fresenius Medical Care AG & Co. KGaA has an analyst consensus of Hold, with a price target consensus of EUR40.23, implying a -14.3% downside from current levels. In a report issued on July 20, J.P. Morgan also maintained a Sell rating on the stock with a EUR28.60 price target.
See the top stocks recommended by analysts >>
Shop Apotheke Europe NV (GB:0RJT)
Credit Suisse analyst Olivier Calvet maintained a Sell rating on Shop Apotheke Europe NV yesterday and set a price target of EUR58.00. The company’s shares closed yesterday at EUR111.20.
Calvet has an average return of
According to TipRanks.com, Calvet is ranked #1515 out of 24810 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Shop Apotheke Europe NV with an EUR117.25 average price target.
Scholar Rock Holding (SRRK)
J.P. Morgan analyst Tessa Romero reiterated a Buy rating on Scholar Rock Holding on July 12 and set a price target of $20.00. The company’s shares closed last Wednesday at $7.32.
According to TipRanks.com, Romero is a 3-star analyst with an average return of
Scholar Rock Holding has an analyst consensus of Strong Buy, with a price target consensus of $19.50, representing a 188.0% upside. In a report issued on June 30, H.C. Wainwright also maintained a Buy rating on the stock with a $30.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GB:0H9X:
- Fresenius Medical resumed with a Neutral at Citi
- 0H9X Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Fresenius Medical price target raised to $28 from $26 at Truist
- Fresenius Medical initiated with a Buy at Goldman Sachs
- Fresenius Medical names Martin Fischer as CFO, succeeding Helen Giza
